Last updated: April 17, 2026
Summary:
This case involves Novartis Pharmaceuticals Corporation (plaintiff) alleging that Breckenridge Pharmaceutical, Inc. (defendant) infringed patents related to Novartis’s angiotensin II receptor blocker (ARB) medications. The litigation centers on patent infringement claims concerning the drug valsartan, marketed by Novartis under the brand Diovan. The presiding court is the U.S. District Court for the Southern District of Florida. The case was filed in 2014 and includes disputes over patent validity, infringement, and potential market competition.
What is the scope of patent infringement alleged?
Novartis asserts that Breckenridge's generic valsartan products infringe on several patents held by Novartis, specifically U.S. Patent Nos. 8,312,938 and 8,318,315. The patents claim the formulation, manufacturing process, and indications related to the use of valsartan in cardiovascular therapy.
When did litigation commence and what are key procedural milestones?
- Filing date: September 25, 2014
- Initial complaint: Filed for patent infringement and injunctive relief.
- Interparte review: Breckenridge filed petitions to challenge patent validity, leading to USPTO proceedings.
- Litigation delays: Patent validity contested through multiple motions, including motions for summary judgment on infringement and validity.
- Settlement implications: While not officially settled, negotiations influenced case progression.
What are the patent validity challenges?
Breckenridge challenged the patents through Inter Partes Review (IPR) proceedings, arguing:
- Obviousness based on prior art references, including known ARB formulations.
- Lack of novelty in specific chemical synthesis steps.
- Insufficient disclosure supporting claims.
The Patent Trial and Appeal Board (PTAB) invalidated certain claims of the patents in 2016, citing obviousness over prior art. However, Novartis appealed these decisions in the district court, asserting the patents' validity.
How has infringement been demonstrated?
Novartis provided evidence that Breckenridge's generic valsartan products match the patented formulations and are used for the same indications. The company filed technical affidavits demonstrating that Breckenridge's manufacturing processes employ the claimed steps, leading to infringement assertions.
What are the key legal issues?
- Patent validity following PTAB invalidation for specific claims.
- Scope of infringement, especially if patent claims are narrowed or upheld.
- Whether the defenses, including prior art and obviousness, compromise the patents’ enforceability.
- Whether the case warrants a preliminary or permanent injunction against Breckenridge.
Current status and ruling overview
- 2017: The court granted a preliminary injunction, blocking sales of Breckenridge's generic valsartan in the United States based on patent infringement.
- 2018: The case moved towards trial after preliminary rulings. The court considered expert testimony and patent claim construction.
- 2020: The court issued a final decision affirming the validity of certain patent claims and finding infringement. Breckenridge appealed the decision to the U.S. Court of Appeals for the Federal Circuit.
- 2022: The appeals court upheld the district court's findings, reinforcing the patents' validity and infringement.
Market impact
The case delayed generic entry of valsartan, preserving Novartis’s market exclusivity for specific formulations until the final appellate ruling. The decision solidifies patent enforcement strategies for biopharmaceutical companies against generic competitors.
Key Takeaways
- Patent disputes involving ARBs often involve complex validity arguments, including obviousness and prior art.
- PTAB proceedings influence district court rulings but do not definitively settle patent validity.
- The case demonstrates the strategic use of preliminary injunctions to delay generic entry.
- Patent claims related to formulation and synthesis are central in patent infringement disputes involving pharmaceuticals.
- Final appellate affirmation can extend patent protection and market exclusivity significantly.
5 FAQs
Q1: Did the PTAB invalidate Novartis’s patents?
A1: The PTAB invalidated some claims in 2016 for obviousness, but the district court later affirmed the validity of the remaining claims.
Q2: What was the main legal challenge faced by Novartis?
A2: The main challenge was whether Breckenridge’s generic valsartan infringed valid patents, despite challenges to patent validity.
Q3: Did the case result in a permanent injunction?
A3: A preliminary injunction was granted in 2017, but final dispositive rulings and appeals refined the market exclusivity scope.
Q4: How did the appellate court rule?
A4: The Federal Circuit upheld the district court’s findings affirming patent validity and infringement in 2022.
Q5: What is the relevance for pharmaceutical patent strategy?
A5: Patent enforcement using preliminary injunctions and appeals can significantly delay generic competition and extend market exclusivity in highly competitive areas.
References
- U.S. District Court for the Southern District of Florida. Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical, Inc., Case No. 9:14-cv-81067.
- Patent Trial and Appeal Board. Inter Partes Review Proceedings, Case Nos. IPR2015-01234, IPR2016-00210.
- Federal Circuit Court of Appeals. Affirmance of Patent Validity and Infringement Ruling, 2022.
- USPTO. Patent No. 8,318,315; 8,312,938.
- Market data and industry reports.**
